An Open-label, Phase 2 Study of ACP-196 in Subjects with Waldenström Macroglobulinemia

Study identifier:ACE-WM-001

ClinicalTrials.gov identifier:NCT02180724

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment Complete

Official Title

An Open-label, Phase 2 Study of ACP-196 in Subjects with Waldenström Macroglobulinemia

Medical condition

Waldenström Macroglobulinemia (WM)

Phase

Phase 2

Healthy volunteers

No

Study drug

Acalabrutinib (ACP-196), Acalabrutinib (ACP-196)

Sex

All

Actual enrollment

107

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 08 Sept 2014
Primary Completion Date: 01 Oct 2019
Estimated Study Completion Date: 31 Dec 2026

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 May 2023 by AcertaPharma

Sponsors

AcertaPharma

Collaborators

-

Inclusion and exclusion criteria